• Home
  • Search Results
  • Human sperm acrosomal status, acrosomal responsiveness, and acrosin are predictive of the outcomes of in vitro fertilization: A prospective cohort study.

Human sperm acrosomal status, acrosomal responsiveness, and acrosin are predictive of the outcomes of in vitro fertilization: A prospective cohort study.

Reproductive biology (2018-11-14)
Fang Xu, Hailun Zhu, Wenbing Zhu, Liqing Fan
ABSTRACT

The sperm acrosome reaction (AR) is a physiological secretory course of membrane fusion and hydrolytic enzymes, as well as matrix protein release, enabling spermatozoa to penetrate the egg surroundings. An instable acrosomal status before a specific stimulus, insufficient acrosomal responsiveness, or inadequate enzymatic activity of acrosomal content can be detrimental to male fertility. This prospective cohort study was designed to determine whether three human sperm acrosome evaluation parameters-including spontaneous AR rate, AR after calcium ionophore A23187 challenge (ARIC) rate, and modified Kennedy acrosin activity-can predict fertilization outcomes in vitro and are correlated with male characteristics. A total of 485 eligible couples undergoing in vitro fertilization (IVF) therapy were included in two phases of this study. In a 'construction phase', three acrosome evaluation parameters were determined simultaneously in 132 cases, whereas in a 'validation phase', the spontaneous AR rate was determined in 353 cases. The results of the 'construction phase' revealed that the spontaneous AR rate was the only significant predictor of fertilization outcome (unadjusted odds ratio [OR] = 0.68, 95% confidence interval [CI]: 0.53-0.88, P =  0.003; adjusted OR = 0.64, 95% CI: 0.43-0.95, P =  0.03), and the cut-off value for total fertilization failure (TFF) prediction, determined by ROC curve analysis, was 9.91%; higher acrosin activity was shown to predict a higher fertilization rate only when patients were divided into groups (≥25 μIU/106 spermatozoa, 14-25 μIU/106 spermatozoa, <14 μIU/106 spermatozoa). The spontaneous AR rate was negatively correlated with sperm motility, forward progression motility, and normal morphology; modified Kennedy acrosin activity was positively correlated with normal morphology; and the ARIC rate was not correlated with any of the male characteristics. A similar result was obtained for the spontaneous AR rate in the 'validation phase', and the cut-off value in predicting TFF was calibrated for 9.52%. Clinically, patients can voluntarily choose spontaneous AR rate alone or in combination with modified Kennedy acrosin activity to predict TFF, and early rescue intracytoplasmic sperm injection (ICSI), half ICSI, or full ICSI should be considered in advance for men with spontaneous AR rates ≥9.52% or spontaneous AR rates ≥9.52% and AE activities <25 μIU/106 spermatozoa.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Dimethyl sulfoxide, Hybri-Max, sterile-filtered, BioReagent, suitable for hybridoma, ≥99.7%
Sigma-Aldrich
Ethyl alcohol, Pure, 200 proof, for molecular biology
Sigma-Aldrich
Triton X-100, laboratory grade
Sigma-Aldrich
HEPES, ≥99.5% (titration)
Sigma-Aldrich
Triton X-100, for molecular biology
SAFC
Phosphate Buffered Saline, pH 7.4, liquid, sterile-filtered, suitable for cell culture
Sigma-Aldrich
Calcium Ionophore A23187, ≥98% (TLC), powder
Sigma-Aldrich
Sodium chloride, anhydrous, Redi-Dri, free-flowing, ACS reagent, ≥99%
Sigma-Aldrich
Nα-Benzoyl-DL-arginine 4-nitroanilide hydrochloride, ≥98%
Sigma-Aldrich
Ficoll® 400, BioXtra, for molecular biology, lyophilized powder
Sigma-Aldrich
Benzamidine hydrochloride, 99%
Sigma-Aldrich
Lectin from Pisum sativum (pea), FITC conjugate, lyophilized powder
Supelco
Calcium ionophore III, Selectophore, function tested

Social Media

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon

MilliporeSigma

Research. Development. Production.

We are a leading supplier to the global Life Science industry with solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production.

© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

Reproduction of any materials from the site is strictly forbidden without permission.